Comparing Costs Associated To Letermovir Prophylaxis Vs Ganciclovir Pre-Emptive Therapy In Hcmv-Seropositive Patients Who Undergone To Hemopoietic Stem Cells Transplantation

INTRODUCTION: Human cytomegalovirus (HCMV) infection is a significant cause of mortality and morbidity after hemopoietic stem cell transplantation (HSCT). Pre-emptive therapy with Ganciclovir (GCV) reduces the risk for HCMV disease but may be associated with significant toxicity. Letermovir (LTV) has been recently approved for prophylaxis of HCMV infection in HCMV-seropositive patients.